|
[1] EVAVOLD CL,KAGAN JC. How inflammasomes inform adaptive immunity[J]. J Mol Biol,2018,430(2):217-237.
|
|
[2] SZABO G,PETRASEK J. Inflammasome activation and function in liver disease[J]. Nat Rev Gastroenterol Hepatol,2015,12(7):387-400.
|
|
[3] HENAO MJ,ELINAV E,JIN C,et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J].Nature,2012,482(7384):179-185.
|
|
[4] STIENSTRA R,TACK CJ,KANNEGANTI TD,et al. The inflammasome puts obesity in the danger zone[J]. Cell Metab,2012,15(1):10-18.
|
|
[5] WANG W,XIAO F,WAN P,et al. EV71 3D protein binds with NLRP3 and enhances the assembly of inflammasome complex[J]. PLo S Pathog,2017,13(1):e1006123.
|
|
[6] CAO Z,FANG Y,LU Y,et al. Melatonin alleviates cadmiuminduced liver injury by inhibiting the TXNIP-NLRP3 inflammasome[J]. J Pineal Res,2017,62(3):e12389.
|
|
[7] ROBBINS GR,WEN H,TING JP. Inflammasomes and metabolic disorders:Old genes in modern diseases[J]. Mol Cell,2014,54(2):297-308.
|
|
[8] TSCHOPP J,SCHRODER K. NLRP3 inflammasome activation:The convergence of multiple signalling pathways on ROS production?[J]. Nat Rev Immunol,2010,10(3):210-215.
|
|
[9] ROBSON SC,SEVIGNY J,ZIMMERMANN H. The E-NTPDase family of ectonucleotidases:Structure function relationships and pathophysiological significance[J]. Purinergic Signal,2006,2(2):409-430.
|
|
[10] KATSNELSON MA,RUCKER LG,RUSSO HM,et al. K+efflux agonists induce NLRP3 inflammasome activation independently of Ca2+signaling[J]. J Immunol,2015,194(8):3937-3952.
|
|
[11] CRUZ CM,RINNA A,FORMAN HJ,et al. ATP activates a reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory cytokines in macrophages[J]. J Biol Chem,2007,282(5):2871-2879.
|
|
[12] MURUVE DA,PETRILLI V,ZAISS AK,et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response[J]. Nature,2008,452(7183):103-107.
|
|
[13] MARTINON F,PETRILLI V,MAYOR A,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome[J].Nature,2006,440(7081):237-241.
|
|
[14] LUAN J,JU D. Inflammasome:A double-edged sword in liver diseases[J]. Front Immunol,2018,9:2201.
|
|
[15] BOARU SG,BORKHAM KE,TIHAA L,et al. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease[J]. J Inflammation,2012,9(1):49.
|
|
[16] WOOLBRIGHT BL,JAESCHKE H. Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure[J]. J Hepatol,2017,66(4):836-848.
|
|
[17] ZIELINSKI CE,MELE F,ASCHENBRENNER D,et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta[J]. Nature,2012,484(7395):514-518.
|
|
[18] TZENG HT,TSAI HF,CHYUAN IT,et al. Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model[J]. PLo S One,2014,9(7):e103008.
|
|
[19] ASKARI A,NOSRATABADI R,KHALEGHINIA M,et al. Evaluation of NLRC4,NLRP1,and NLRP3,as components of inflammasomes,in chronic hepatitis B virus-infected patients[J]. Viral Immunol,2016,29(9):496-501.
|
|
[20] YU X,LAN P,HOU X,et al. HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1beta production via suppressing the NF-kappaB pathway and ROS production[J]. J Hepatol,2017,66(4):693-702.
|
|
[21] GOWER E,ESTES C,BLACH S,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[J].J Hepatol,2014,61(1 Suppl):s45-s57.
|
|
[22] TANG H,GRISE H. Cellular and molecular biology of HCV infection and hepatitis[J]. Clin Sci,2009,117(2):49-65.
|
|
[23] NEGASH AA,OLSON RM. Modulation of calcium signaling pathway by hepatitis C virus core protein stimulates NLRP3 inflammasome activation[J]. PLo S Pathog,2019,15(2):e1007593.
|
|
[24] MCRAE S,IQBAL J,SARKAR-DUTTA M,et al. The hepatitis C virus-induced NLRP3 inflammasome activates the sterol regulatory element-binding protein(SREBP)and regulates lipid metabolism[J]. J Biol Chem,2016,291(7):3254-3267.
|
|
[25] NEGASH AA,GALE M,JR. Hepatitis regulation by the inflammasome signaling pathway[J]. Immunol Rev,2015,265(1):143-155.
|
|
[26] CHEN W,XU Y,LI H,et al. HCV genomic RNA activates the NLRP3 inflammasome in human myeloid cells[J]. PLo S One,2014,9(1):e84953.
|
|
[27] FARAG NS,BREITINGER U,EL-AZIZI M,et al. The p7 viroporin of the hepatitis C virus contributes to liver inflammation by stimulating production of Interleukin-1beta[J]. Biochim Biophys Acta Mol Basis Dis,2017,1863(3):712-720.
|
|
[28] CAMPANA L,IREDALE JP. Regression of liver fibrosis[J].Semin Liver Dis,2017,37(1):1-10.
|
|
[29] LEE UE,FRIEDMAN SL. Mechanisms of hepatic fibrogenesis[J]. Best Pract Res Clin Gastroenterol,2011,25(2):195-206.
|
|
[30] ALEGRE F,PELEGRIN P,FELDSTEIN AE. Inflammasomes in liver fibrosis[J]. Semin Liver Dis,2017,37(2):119-127.
|
|
[31] WREE A,MCGEOUGH MD,INZAUGARAT ME,et al. NLRP3inflammasome driven liver injury and fibrosis:Roles of IL-17and TNF in mice[J]. Hepatology,2018,67(2):736-749.
|
|
[32] HE K,ZHU X,LIU Y,et al. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development[J]. Oncotarget,2017,8(23):37657-37672.
|
|
[33] ARTLETT CM,THACKER JD. Molecular activation of the NLRP3 Inflammasome in fibrosis:Common threads linking divergent fibrogenic diseases[J]. Antioxid Redox Signal,2015,22(13):1162-1175.
|
|
[34] INZAUGARAT ME,JOHNSON CD,HOLTMANN TM,et al.NLR family pyrin domain-containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice[J].Hepatology,2019,69(2):845-859.
|
|
[35] ASRIH M,JORNAYVAZ FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance[J]. J Endocrinol,2013,218(3):r25-r36.
|
|
[36] PEVERILL W,POWELL LW,SKOIEN R. Evolving concepts in the pathogenesis of NASH:Beyond steatosis and inflammation[J]. Int J Mol Sci,2014,15(5):8591-8638.
|
|
[37] THOMAS H. NAFLD:A critical role for the NLRP3 inflammasome in NASH[J]. Nat Rev Gastroenterol Hepatol,2017,14(4):197.
|
|
[38] AFONINA IS,ZHONG Z,KARIN M,et al. Limiting inflammation-the negative regulation of NF-κB and the NLRP3 inflammasome[J]. Nat Immunol,2017,18(8):861-869.
|
|
[39] BROZ P,DIXIT VM. Inflammasomes:Mechanism of assembly,regulation and signalling[J]. Nat Rev Immunol,2016,16(7):407-420.
|
|
[40] ELLIOTT EI,SUTTERWALA FS. Initiation and perpetuation of NLRP3 inflammasome activation and assembly[J]. Immunol Rev,2015,265(1):35-52.
|
|
[41] MILLS EL,KELLY B,O'NEILL LAJ. Mitochondria are the powerhouses of immunity[J]. Nat Immunol,2017,18(5):488-498.
|
|
[42] ZHANG B,XU D,SHE L,et al. Silybin inhibits NLRP3 inflammasome assembly through the NAD(+)/SIRT2 pathway in mice with nonalcoholic fatty liver disease[J]. FASEB J,2018,32(2):757-767.
|
|
[43] ZHOU F,ZHANG Y,CHEN J,et al. Verapamil Ameliorates Hepatic Metaflammation by Inhibiting Thioredoxin-Interacting Protein/NLRP3 Pathways[J]. Front Endocrinol,2018,9:640.
|
|
[44] CHEN XG,MIN XX,YU TQ,et al. Loss of RIP3 initiates annihilation of high-fat diet initialized nonalcoholic hepatosteatosis:A mechanism involving Toll-like receptor 4 and oxidative stress[J]. Free Radical Biol Med,2018,134:23-41.
|
|
[45] ZHU W,FENG PP,HE K,et al. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet[J].Biochem Biophys Res Commun,2018,505(2):523-529.
|
|
[46] MRIDHA AR,WREE A,ROBERTSON AAB,et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J]. J Hepatol,2017,66(5):1037-1046.
|
|
[47] PATEL P,OKORONKWO N,PYRSOPOULOS NT. Future approaches and therapeutic modalities for acute liver failure[J].Clin Liver Dis,2018,22(2):419-427.
|
|
[48] HAN DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure[J]. World J Gastroenterol,2002,8(6):961-965.
|
|
[49] GONG X,YANG Y,HUANG L,et al. Antioxidation,anti-inflammation and anti-apoptosis by paeonol in LPS/d-Gal Ninduced acute liver failure in mice[J]. Int Immunopharmacol,2017,46:124-132.
|
|
[50] WANG J,REN H,YUAN X,et al. Interleukin-10 secreted by mesenchymal stem cells attenuates acute liver failure through inhibiting pyroptosis[J]. Hepatol Res,2018,48(3):e194-e202.
|
|
[51] BAK J,JE NK,CHUNG HY,et al. Oligonol ameliorates CCl(4)-induced liver injury in rats via the NF-kappa B and MAPK signaling pathways[J]. Oxid Med Cell Longevity,2016,2016:3935841.
|
|
[52] XING T,LI L,CAO H,et al. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure[J]. Clin Exp Immunol,2007,147(1):184-188.
|
|
[53] ZHAO Q,WU CS,FANG Y,et al. Glucocorticoid regulates NLRP3 in acute-on-chronic hepatitis B liver failure[J]. Int J Med Sci,2019,16(3):461-469.
|
|
[54] DEL CAMPO JA,GALLEGO P,GRANDE L. Role of inflammatory response in liver diseases:Therapeutic strategies[J].World J Hepatol,2018,10(1):1-7.
|
|
[55] LV H,QI Z,WANG S,et al. Asiatic acid exhibits anti-inflammatory and antioxidant activities against lipopolysaccharide and d-galactosamine-induced fulminant hepatic failure[J].Front Immunol,2017,8:785.
|
|
[56] PAN CW,PAN ZZ,HU JJ,et al. Mangiferin alleviates lipopolysaccharide and D-galactosamine-induced acute liver injury by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation[J]. Eur J Pharmacol,2016,770:85-91.
|
|
[57] LIU X,WANG T,LIU X,et al. Biochanin A protects lipopolysaccharide/D-galactosamine-induced acute liver injury in mice by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation[J]. Int Immunopharmacol,2016,38:324-331.
|
|
[58] JIANG L,ZHANG S,HU H,et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acute liver failure by reducing the activity of the NLRP3 inflammasome in macrophages[J]. Biochem Biophys Res Commun,2019,508(3):735-741.
|
|
[59] WANG Z,ZHANG G,WU J,et al. Adjuvant therapy for hepatocellular carcinoma:Current situation and prospect[J]. Drug Discov Ther,2013,7(4):137-143.
|
|
[60] MORIMOTO O,NAGANO H,SAKON M,et al. Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas[J]. J Hepatol,2003,39(2):215-221.
|
|
[61] NOMOTO S,HISHIDA M,INOKAWA Y,et al. Expression analysis of THOP1 in background liver,a prognostic predictive factor in hepatocellular carcinoma,extracted by multiarray analysis[J]. Ann Surg Oncol,2014,21(Suppl 3):s443-s450.
|
|
[62] FAN SH,WANG YY,LU J,et al. Luteoloside suppresses proliferation and metastasis of hepatocellular carcinoma cells by inhibition of NLRP3 inflammasome[J]. PLo S One,2014,9(2):e89961.
|
|
[63] SONOHARA F,INOKAWA Y,KANDA M,et al. Association of inflammasome components in background liver with poor prognosis after curatively-resected hepatocellular carcinoma[J].Anticancer Res,2017,37(1):293-300.
|
|
[64] WEI Q,GUO P,MU K,et al. Estrogen suppresses hepatocellular carcinoma cells through ERbeta-mediated upregulation of the NLRP3 inflammasome[J]. Lab Invest,2015,95(7):804-816.
|
|
[65] STROWIG T,HENAO-MEJIA J,ELINAV E,et al. Inflammasomes in health and disease[J]. Nature,2012,481(7381):278-286.
|
|
[66] ZITVOGEL L,KEPP O,GALLUZZI L,et al. Inflammasomes in carcinogenesis and anticancer immune responses[J]. Nat Immunol,2012,13(4):343-351.
|
DownLoad: